

The Board of Pharmacy has received notice of the following product withdrawal. The Board strongly encourages pharmacies to immediately review their quality assurance and recall policies and procedures to determine if any corrective action is required.

Lupin Pharmaceuticals Inc. is initiating a market withdrawal of lot **L001323, Expiry July 2022**, of **Levothyroxine Sodium Tablets USP, 137mcg (0.137mg)** to the retail level. Out of an abundance of caution, this lot is being withdrawn due to an out of trend result observed in an assay test at the six-month stability time point. The out of trend result was within the specification limit, and therefore it is unlikely to cause any effect or impact patient safety.

The withdrawn lot was distributed between November 23, 2020, and December 28, 2020, to wholesalers and distributors nationwide.

<b>Strength</b>	<b>Lot No</b>	<b>NDC</b>	<b>Pack Size</b>	<b>Description</b>
137mcg (0.137mg)	L001323	68180-972-01	100's count	Levothyroxine Sodium Tablets USP, 137mcg (0.137mg) are turquoise/round, scored and debossed with L23 on one side and break-line on other side.